DBV Technologies S.A. (DBVT) Stock Analysis

Q: What is the DBVT stock price target?

Take-profit $34.81 (+66.6% upside). Prior stop was $19.43.

Q: Is DBVT overvalued or undervalued?

DBV Technologies S.A. trades at a P/E of N/A (forward -76.7). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about DBVT?

8 analysts cover DBVT with a consensus score of 4.0/5. Average price target: $40.

Breakout setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $20.88: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 7.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.

$20.88+66.6% A.UpsideScore 6.2/10#13 of 158 Biotechnology

Stop $19.43Target $34.81(analyst − 13%)A.R:R 7.2:1

Analyst target$40.01+91.6%6 analysts

$34.81our TP

$20.88price

$40.01mean

$52

Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (3.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-76.7

Mkt Cap$1.2B

EV/EBITDA-31.9

Profit Mgn0.0%

ROE-149.8%

Rev Growth26.2%

Beta-0.20

DividendNone

Rating analysts8

Quality Signals

Piotroski F4/9

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·2 ceiling hits

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality3.515%0.53

Growth9.015%1.35

Momentum6.110%0.61

Sentiment7.310%0.73

Insider Activity7.010%0.70

Peer Rank3.410%0.34

Technical Setup5.25%0.26

Risk Profile3.65%0.18

Catalyst2.55%0.13

Overall (Σ contributions)6.17

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 0 days

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

5.0

Growth Rank

5.7

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Piotroski F

4.4

Moat

5.0

Current Ratio

9.3

Gross Margin

10.0

Cash-burning: FCF -1141% of revenueNo competitive moatRule of 40: -1114 (fail)

GatesEARNINGS PROXIMITY 0d<=7dMomentum 6.1>=5.5A.R:R 7.2 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARBreakoutSuitability: Aggressive

RSI

52 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.15Resistance $23.04

Price Targets

$19

$35

A.Upside+66.7%

A.R:R7.2:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.5 < 4.0)

! EARNINGS_PROXIMITY:0d<=7d

Earnings

1/4 beats

Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is DBVT stock a buy right now?

Sell if holding. Engine safety override at $20.88: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 7.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Prior stop was $19.43. Score 6.2/10, moderate confidence.

What is the DBVT stock price target?

Take-profit target: $34.81 (+66.6% upside). Prior stop was $19.43. Stop-loss: $19.43.

What are the risks of investing in DBVT?

Quality below floor (3.5 < 4.0).

Is DBVT overvalued or undervalued?

DBV Technologies S.A. trades at a P/E of N/A (forward -76.7). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about DBVT?

8 analysts cover DBVT with a consensus score of 4.0/5. Average price target: $40.

What does DBV Technologies S.A. do?DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of...

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.